The European regulator could approve the introduction of Covid-19 vaccines produced by US development company Moderna and Pfizer / BioNTech from mid-December, European Commission President Ursula von der Leyen said on Thursday.
The European Medicines Agency (EMA) is "in talks" with the US FDA on a daily basis to "reconcile its assessments" and the EMA could "grant conditional approval for the introduction of Pfzier / BioNTech and Moderna as early as the second half of December," the head of the European executive said after the European summit.
The virtual summit of twenty-seven countries was dedicated to the coronavirus pandemic.
Moderna and Pfizer / BioNTech announced this week that their vaccines are effective in 95 percent of cases and will seek extraordinary approval in the coming days.
The success of the two vaccines has sparked hopes for an end to the Covid-19 pandemic, which so far has claimed 1.3 million lives worldwide and dealt a severe blow to economies and daily life.
But it will take a few more months before the vaccine is widely used, although priority groups like healthcare workers in the U.S. will receive it as early as this year.
The companies reiterated that they expect to produce 50 million doses of the vaccine by the end of this year, enough to protect 25 million people, and up to 1.3 billion doses next year.